A method for the production of monoclonal antibodies in mammal's milk, through the creation of transgenic animals that selectively express foreign antibody genes in mammary epithelial cells.

Transgenic production of antibodies in milk

Provided herein are a variety of methods and compositions for regulating angiogenesis, such methods and compositions being useful in a variety of applications where modulation of vascular formation is useful, including, but not limited to, treatments for ischemia and wound healing. Certain of the methods and compositions accomplish this by using various zinc finger proteins that bind to particular target sites in one or more VEGF genes. Nucleic acids encoding the zinc finger proteins are also disclosed. Methods for modulating the expression of one or more VEGF genes with the zinc finger proteins and nucleic acids are also disclosed. Such methods can also be utilized in a variety of therapeutic applications that involve the regulation of endothelial cell growth. Pharmaceutical compositions including the zinc finger proteins or nucleic acids encoding them are also provided.

Regulation of angiogenesis with zinc finger proteins

Provided are methods of treatment for skin disorders. In particular, treatment, the skin disorders are generally inflammatory skin disorders, including improper wound healing. Provided are methods of using of a cytokine molecule.

Uses of mammalian cytokine; related reagents

The present invention provides for identification and use of small molecules to induce pluripotency in mammalian cells as well as other methods of inducing pluripotency.

Combined chemical and genetic approaches for generation of induced pluripotent stem cells

The disclosure relates to a method of reprogramming one or more somatic cells, e.g., partially differentiated or fully/terminally differentiated somatic cells, to a less differentiated state, e.g., a pluripotent or multipotent state. In further embodiments the invention also relates to reprogrammed somatic cells produced by methods of the invention, to uses of said cells, and to methods for identifying agents useful for reprogramming somatic cells.

Reprogramming of somatic cells

Transgenic non-human animals with a human interleukin-1β gene under control of the murine metallothionein-1 promoter are provided. The transgenic animals and cell cultures derived therefrom may be used to study inflammation and cognitive disorders.

EXPRESSION OF HUMAN INTERLEUKIN-1-g(b) IN A TRANSGENIC ANIMAL

Transgenic mice with a human interleukin 1β gene is provided. The transgenic mice may be used to evaluate compounds affecting Alzheimer's Disease and other cognitive disorders.

Transgenic animal model for cognitive disorders

Cells and non-human transgenic animals have been engineered to be deficient in the gene encoding agouti-related protein (AgRP). AgRP deficient transgenic animals have a reduced day time respiratory quotient (RQ), indicating that AgRP is involved in the regulation of energy metabolism, resulting in the reduced usage of fat as an energy source. These AgRP deficient transgenic animals can be used to select for and test potential modulators of AgRP. This data allows for methods of screening for AgRP modulators which regulate energy metabolism and caloric utilization. The disclosure also relates to a NPY/AgRP double knockout mouse which can be used to select for and test potential modulators (e.g., agonists or antagonists) of AgRP and/or NPY.

Agouti-related protein deficient cells, non-human transgenic animals and methods of selecting compounds which regulate energy metabolism

A transgenic animal with alterations in an IL-1β gene is prepared by introduction of a gene encoding an altered IL-1β gene into a host animal.

INTERLEUKIN-1$g(b) DEFICIENT TRANSGENIC ANIMALS

The present invention relates to a transgenic nonhuman animal lacking native amyloid precursor protein. The transgenic mouse of the invention may be used in the study of Alzheimer's Disease and disorders involving the central nervous system.

Der Ploeg Leonardus H. T. Van

Papers

EXPRESSION OF HUMAN INTERLEUKIN-1-g(b) IN A TRANSGENIC ANIMAL

Transgenic animal model for cognitive disorders

Agouti-related protein deficient cells, non-human transgenic animals and methods of selecting compounds which regulate energy metabolism

INTERLEUKIN-1$g(b) DEFICIENT TRANSGENIC ANIMALS

Transgenic animal lacking native amyloid precursor protein